632 results on '"Palapattu, Ganesh S."'
Search Results
2. MyProstateScore in men considering repeat biopsy: validation of a simple testing approach
3. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations
4. Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma
5. Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249).
6. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer
7. Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature
8. Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature
9. Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer
10. Psoas Muscle Mass can Predict Postsurgical Outcomes in Patients Who Undergo Radical Cystectomy and Urinary Diversion Reconstruction
11. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
12. Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype
13. COVID and CopMich: comparing and contrasting COVID-19 experiences in the USA and Scandinavia
14. Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
15. Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice
16. De novo neuroendocrine transdifferentiation in primary prostate cancer–a phenotype associated with advanced clinico-pathologic features and aggressive outcome
17. Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
18. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma
19. Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer?
20. Prostate cancer: metastatic
21. Development and Validation of MyProstateScore 2.0 to Detect Clinically Significant Prostate Cancer
22. Data from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature
23. Supplementary Figures S1 - S6, Tables S1 - S2 from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature
24. Supplementary material from Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer
25. Data from Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression
26. Supplementary Methods, Figures 1-5, Tables 1-11 from Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression
27. Categorizing renal oncocytic neoplasms on core needle biopsy: a morphologic and immunophenotypic study of 144 cases with clinical follow-up
28. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
29. Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series
30. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling
31. Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series
32. MyProstateScore in men considering repeat biopsy: validation of a simple testing approach
33. Reporting standards for the imaging-based diagnosis of renal masses on CT and MRI: a national survey of academic abdominal radiologists and urologists
34. Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations
35. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer
36. Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections
37. Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology
38. Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients
39. Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need
40. PD13-06 COMPREHENSIVE RETROSPECTIVE ASSESSMENT OF CLINICAL OUTCOMES WITH RADICAL PROSTATECTOMY AND RADIOTHERAPY IN PROSTATE CANCER REVEALS INADEQUACIES IN OBSERVATIONAL DATASETS
41. Larger Maximum Tumor Diameter at Radical Prostatectomy Is Associated With Increased Biochemical Failure, Metastasis, and Death From Prostate Cancer After Salvage Radiation for Prostate Cancer
42. Factors Associated with the Adoption of Minimally Invasive Radical Prostatectomy in the United States
43. The role of spatial transcriptomic profiling to determine androgen receptor signaling and immune infiltration in prostate cancer
44. Molecular characterization to delineate the clonal evolution of primary prostate cancer with synchronous lymph node metastasis.
45. Validation of a 22-gene epithelial-mesenchymal transition (EMT) prognostic signature in clear cell renal cell carcinoma.
46. Prognostic value and therapeutic implications of an integrative molecular subtype and immune content classifier in localized muscle-invasive bladder cancer.
47. Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen
48. Prostate cancer clinical trial completion: The role of geography
49. Parsing Multi-omic Data to Understand Urothelial Cell Carcinoma Progression
50. COMPARISON OF ACCURACY OF RISK-STRATIFICATION OF SMALL RENAL MASSES (SRMS) WITH ALGORITHM BASED ON PERCUTANEOUS RENAL MASS BIOPSY (RMB) AND MASS SIZE VERSUS NOMOGRAMS BASED ON R.E.N.A.L. NEPHROMETRY SCORE (RNS): MP73-03
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.